{"doi":"10.5281/zenodo.3953830","title":"Unknown","abstract":null,"journal":null,"year":null,"id":624909,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A study of Convalescent Plasma Therapy for COVID-19 Patients","abstract":"The novel coronavirus (nCoV) has spread around the world as an epidemic. As of July 06, 2020, the number of victims has already crossed 11.5 million and the number of deaths has exceeded 537K and is steading rising.In the past convalescent plasma (CCP) therapy was used in many epidemics. Already many people have successfully recovered from sever acute respiratory syndrome Corona virus 2 (SARS-CoV-2) and have developed antibodies in their plasma to fight the virus.They have this plasma very effective for critical patients. Many countries are currently trying to develop effective vaccines. They have already done various trials of their vaccines . Until a suitable vaccine for this disease is developed, CCP therapy can be used in severe patients.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W3047340952","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.06240186,"influential_citations":0,"citation_trend":[],"oa_status":"green","license":"cc-by","oa_locations":[{"url":"https://zenodo.org/record/3953830","host_type":"repository"},{"url":"https://ideas.repec.org/a/aif/journl/v4y2020i8p17-22.html","host_type":"journal"},{"url":"https://ijsab.com/volume-4-issue-8/3115","host_type":"repository"},{"url":"https://doi.org/10.5281/zenodo.3953830","host_type":"repository"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","Cannabis and Cannabinoid Research","COVID-19 diagnosis using AI"],"mesh_terms":[],"keywords":["Convalescent plasma","Coronavirus disease 2019 (COVID-19)","Medicine","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Virology","Intensive care medicine","Coronavirus","Virus","Disease","Immunology","Infectious disease (medical specialty)","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T05:13:27.574393Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}